Kornimate/medical-research-clean huggingface dataset:
research study in patients with persistent macular edema

Conditions: Diabetes; Macular Edema; Diabetic Retinopathy; Retinal Disease; Uveitis, Posterior

Summary: the purpose of this clinical research study is to evaluate the safety and effectiveness of an investigational medication to treat macular edema that persists despite current treatment methods. participants will be evaluated for improvement in vision and side effects. macular edema is a condition that affects the back of the eye (retina). it frequently occurs in people who have a history of diabetes, and is also associated with high blood pressure, uveitis, and previous eye surgery. the main symptom of macular edema is decreased vision, generally a blurring of central vision. there are no direct costs to participants for assessments and treatment as defined in the study protocol. all candidates must be available for required scheduled visits during the trial's 6-month follow-up period. although the disease called age-related macular degeneration (amd) affects the same region of the eye as macular edema, they are not the same condition and amd is not studied in this research trial.


Eligibility criteria:
inclusion: persistent macular edema associated with diabetic retinopathy, uveitis, retinal vein occlusion, or irvine-gass syndrome, persisting at least 90 days after laser treatment or medical management by a physician. exclusion: females who are pregnant or lactating, and females of childbearing potential not using adequate birth control for the duration of the study. any intraocular procedures or laser treatment less than 90 days before enrollment.

Keywords: diabetes macular edema diabetic macular edema diabetic retinopathy cystoid macular edema uveitis vision eye retina retinal vein occlusion irvine-gass syndrome
can video clips improve patient comprehension at the emergency department?

Conditions: Doctor Patient Communication; Patient Safety; New Technologies in Clinical Medicine; Patient Education and Health Literacy; Safe Hospital Discharge

Summary: the aim of this study is to assess the utility of two interventional videos, showed to patients discharged from the ed with a diagnosis of atrial fibrillation or deep vein thrombosis. we have focused our attention on these two medical conditions because they share some important features: they are frequently seen in eds; their main complication (stroke and pulmonary embolism) can cause significant morbidity and mortality; both conditions and their related complications are probably not very intuitive to comprehend for the general population. in fact, the understanding of these conditions implies the knowledge of a number of pathological processes, with which most people are unfamiliar. the primary hypothesis is that patients enrolled in the study group will show a higher degree of comprehension of their medical condition and its related complications, as compared to the control group. secondly, we will also analyze any possible effect of the videos on the knowledge of the therapy prescribed, return instructions and patients' satisfaction with the quality of communication in the ed. eventually, we will examine the association of some factors with the outcomes (age, sex, level of education, atrial fibrillation vs. deep vein thrombosis group).


Eligibility criteria:
* age \>18 * being diagnosed with one of the two medical condition under study: patients with first-time diagnosis of deep vein thrombosis; patients with first-time diagnosis of atrial fibrillation; patients with second episode in life of atrial fibrillation who have never been prescribed take-home medications for its cure or prevention of recurrence (anticoagulants, antiarrhythmic drugs including beta-blockers) * being discharged home directly from the emergency department/emergency unit * capacity of the patient to understand the explanations and instructions provided by the doctor (this includes excellent command of the italian language) * having provided a valid phone number * having signed the informed consent in case of patients lacking capacity, and in all cases of patients who will be judged by the recruiting doctor as incapable to safely receive the discharge instructions, the caregiver will be enrolled to the study with identical modalities. in the context of a pragmatic trial, we did not set exclusion criteria in terms of education level and comorbidities of the enrolled patients. exclusion criteria: * previous diagnosis of deep vein thrombosis * two or more previous episodes of atrial fibrillation; or one previous episode of atrial fibrillation for which the patient has been prescribed one of the following take-home medications: anticoagulants, antiarrhythmic drugs including beta-blockers. * being hospitalized
randomized study of obicetrapib as an adjunct to statin therapy

Conditions: Dyslipidemias; High Cholesterol; Hypercholesterolemia

Summary: this study will be a placebo-controlled, double-blind, randomized, phase 2 dose-finding study to evaluate the efficacy, safety, and tolerability of obicetrapib as an adjunct to high-intensity statin therapy.

this study will be a placebo-controlled, double-blind, randomized, phase 2 dose-finding study to evaluate the efficacy, safety, and tolerability of obicetrapib as an adjunct to high-intensity statin therapy. the screening period for this study will take up to 2-weeks. afterwards patients will be randomized to placebo, 5 mg obicetrapib or 10 mg obicetrapib for an 8-week treatment period. after the treatment period, patients will continue for a 4-week safety follow-up and a 15-week pk follow-up.

Eligibility criteria:
inclusion criteria: * ldl-c \> 70 mg/dl and tg \< 400 mg/dl, * treated with a high-intensity statin therapy exclusion criteria: * bmi \> 40 kg/m * significant cardiovascular disease * hba1c \> 10% * uncontrolled hypertension * active muscle disease * gfr \< 60 ml/min * hepatic dysfunction * anemia * history of malignancy * alcohol abuse * treatment with investigational product * treatment with pcsk9 * clinically significant condition * known cetp inhibitor allergy

Keywords: obicetrapib statin ldl-c cholesterol atherosclerosis
abdominal binder following cesarean delivery

Conditions: Cesarean Section Complications

Summary: cesarean delivery is a common obstetrical procedure and is associated with increased maternal morbidity and mortality. pain and limited mobilization are major contributing factors that result in delayed functional recovery and complications. elastic abdominal binder, a wide elastic belt that is wore around the patient's abdomen to support surgical incision after surgery, has been employed by clinicians for pain relief, wound complications prevention, improved pulmonary function, and stabilization. benefits of the abdominal binder use have not been properly examined. the aim of this study is to examine the effect of postcesarean elastic abdominal binder use on recovery by comparing pain scores and mobility function (through the 6-minute walk test \[6mwt\]) in postcesarean mothers who use versus do not use the elastic abdominal binder to support incisional site.


Eligibility criteria:
inclusion criteria: * pregnant women undergoing cesarean delivery exclusion criteria: * cesarean hysterectomy * intraoperative accidental injury to urinary or gastrointestinal organs * postoperative admission to intensive care unit (icu) * postoperative intraperitoneal drain placement * unable to understand and follow oral/written instructions * severe neuromuscular or circulatory disorders * pulmonary diseases
myasthenia gravis and psyche

Conditions: Myasthenia Gravis

Summary: the purpose of the study is to systematically capture and characterize mental comorbidities for patients with myasthenia gravis. anxiety disorders and depression for example, can negatively affect the quality of life and lead to e.g. unemployment and early retirement especially in young patients. additionally the researchers want to find out in what way certain aspects of the disease have an influence on the quality of life, and whether different concepts of coping with the disease have different effects on the quality of life for patients with myasthenia gravis. during the study, close relatives of patients will also be asked to provide input about their current stress situation in the context of supporting their relative. based on the results, the investigators want to improve and supplement established treatment concepts, to ensure a more comprehensive and individual treatment.


Eligibility criteria:
inclusion criteria: * patients with myasthenia gravis * age ≥18 years exclusion criteria: * n/a

Keywords: myasthenia gravis psyche depression anxiety disorder posttraumatic stress disorder disease processing
pulpotomy as a treatment of irreversible pulpitis

Conditions: Irreversible Pulpitis

Summary: the procedure currently recommended for the treatment of irreversible pulpitis is the endodontic treatment, i.e. the complete elimination of the pulp, disinfection and obturation of the whole root canal system. the emergency procedure consists of a pulpotomy, followed at an ulterior appointment by the root canal treatment. the purpose of the present pilot study is to evaluate the feasibility of performing the pulpotomy as a permanent treatment in mature molars. if hemostasis can be achieved after removing the coronal part of the pulp, a tricalcium silicate cement will be directly applied on the remaining pulp at the root canal entrances. a short-term follow-up will be performed at one week by evaluating the pain relief of the patient. long-term success will then be evaluated every year by verifying the absence of periapical radiolucency on the x-ray as well as the absence of clinical symptoms and signs. a standard root canal procedure will serve as control. during the pulpotomy treatment, blood sample with microcapillary will be performed. we will analyze a ratio of pro-inflammatory and anti-inflammatory cytokines.


Eligibility criteria:
inclusion criteria: * good general health * not pregnant women * at least one permanent molar in irreversible pulpitis * adult patient * mentally competent exclusion criteria: * periapical radiolucency * periodontical probing * root fracture * sinus tract * swelling or mobility * external or/and internal resorption * open apicies * a non restorable tooth

Keywords: pulpotomy pulpitis mature tooth tricalcium silicate
obese human beta-2-adrenergic stimulation and muscle glucose uptake

Conditions: Type 2 Diabetes

Summary: the purpose of this study is to investigate the effect of four weeks clenbuterol/placebo supplementation on skeletal muscle glucose disposal in overweight/obese male and (postmenopausal) female volunteers.


Eligibility criteria:
inclusion criteria: 1. caucasian; 2. male or (postmenopausal; defined as 1 year after the last cycle) female; 3. age between 40-70 years; 4. bmi: 27-35 kg/m2; exclusion criteria: 1. not meeting all inclusion criteria 2. cardiovascular disease (determined by means of questionnaires, heart rate/blood pressure measurements and an ecg) 3. respiratory diseases (including asthma, bronchitis and copd); 4. unstable body weight (weight gain or loss \> 3 kg in the last three months); 5. intention to lose or gain body weight (e.g. with caloric restriction or physical activity) 6. excessive alcohol and/or drug abuse; 7. hypokalaemia; 8. hyperthyroidism 9. anaemia; 10. epilepsy; 11. smoking; 12. renal and/or liver insufficiency; 13. diagnosed with type 1 or type 2 diabetes mellitus; 14. any contra-indications to mri scanning. these contra-indications include patients with: 1. electronic implants such as pacemakers, defibrillators or neurostimulators 2. central nervous system aneurysm clip 3. some hearing aids (such as cochlear implant) and artificial (heart) valves which are contraindicated for mri/mrs 4. iron containing corpora aliena in the eye or brains 5. claustrophobia 15. participation in another biomedical study within 1 month before the first study visit, possibly interfering with the study results; 16. medication use known to hamper subject's safety during the study procedures; 17. subjects who do not want to be informed about unexpected medical findings; 18. subjects who do not want that their treating physician to be informed; 19. inability to participate and/or complete the required measurements; 20. participation in organised or structured physical exercise (\>2h per week); 21. any condition, disease or abnormal laboratory test result that, in the opinion of the investigator, would interfere with the study outcome, affect trial participation or put the subject at undue risk;
short-term clinical performance of multifocal soft contact lens

Conditions: Myopia

Summary: the study is aimed to observe the short-term clinical performance of misight™ multifocal soft contact lens compared with proclear™ 1day, including objective examination, subjective acceptability of wearers, and doctors' evaluation of the clinical manifestations of lenses.

compared with proclear™ 1day, observe the short-term clinical performance of misight™ multifocal soft contact lens including objective examination, subjective acceptability of wearers, and doctors' evaluation of the clinical manifestations of lenses in 1 month.

Eligibility criteria:
inclusion criteria: * • prior to being considered eligible to participate in this study, each subject must: 1. be between 8 and 12 years of age inclusive at the baseline examination. 2. have: 1. read the informed assent, 2. been given an explanation of the informed assent, 3. indicated an understanding of the informed assent and 4. signed the informed assent form. 3. have their parent or legal guardian: 1. read the informed consent, 2. been given an explanation of the informed consent, 3. indicated an understanding of the informed consent and 4. signed the informed consent form. 4. along with their parent or guardian, be capable of comprehending the nature of the study and be willing and able to adhere to the instructions set forth in this protocol. 5. along with their parent or guardian, agree to maintain the visit schedule and be able to keep all appointments as specified in the study protocol for the duration of the study. 6. agree to wear the assigned contact lenses for the duration of the 1-month study and to inform the study investigator if this schedule is interrupted. (wearing time may be modified by the study staff for health reasons.) 7. meet the following refractive criteria determined by cycloplegic autorefraction at baseline: 1. spherical refractive error： between -0.75 and -4.00 d inclusive, 2. astigmatism: ≤-0.75 d, 3. anisometropia: ≤1.50d, 8. best-corrected visual acuity :≥0.8. exclusion criteria: * • subjects may not be considered eligible if any of the following apply: 1. subject has regular use of ocular medications. 2. any systemic disease which is not suggested to wear contact lens or current use of systemic medications which may significantly affect contact lens wear, visual function, or refractive state. 3. a history of ocular trauma or ocular surgery in the last 8 weeks. 4. subject has worn rigid gas permeable contact lenses in the last 6 weeks, including orthokeratology lenses. 5. abnormal secretion or excretion of tear fluid, infection of the tear ducts, or other recurrent ocular infections. 6. a known allergy to fluorescein, benoxinate, proparacaine, or tropicamide. 7. keratoconus or an irregular cornea. 8. subjects who have been in a special environment such as dryness, serious dust, or volatile chemicals for a long time affect the wear of contact lenses. 9. strabismus, amblyopia patients, only one eye meets the admission conditions. 10. subjects have received any myopia control treatment. 11. subject is currently an active participant in another clinical study.
study of bhv-3241 in participants with multiple system atrophy

Conditions: Multiple System Atrophy

Summary: the purpose of this study is to compare the efficacy of verdiperstat (bhv-3241) versus placebo in participants with multiple system atrophy


Eligibility criteria:
inclusion criteria: 1. diagnosis of probable or possible msa according to consensus clinical criteria (gilman et al 2008), including participants with msa of either subtype (msa-p or msa-c). 2. able to ambulate without the assistance of another person, defined as the ability to take at least 10 steps. use of assistive devices (e.g., walker or cane) is allowed. 3. anticipated survival of at least 3 years at the time of screening, as judged by the investigator. exclusion criteria: 1. any condition that would interfere with the participant's ability to comply with study instructions, place the participant at unacceptable risk, and/or confound the interpretation of safety or efficacy data from the study, as judged by the investigator. 2. diagnosis of neurological disorders, other than msa.

Keywords: multiple system atrophy (msa)
a combination of ibuprofen with curcumin covered with liquorice root supplementation in the management of postoperative dental pain in adults

Conditions: Dental Pain

Summary: dental pain, a common issue in stomatology, requires a multifaceted treatment approach. this study explores the efficacy of combining ibuprofen with curcumin and liquorice root supplements for managing postoperative dental pain. curcumin, known for its antioxidant and anti-inflammatory properties, along with liquorice root, may enhance pain relief beyond conventional nsaids like ibuprofen. this randomized, double-blind, placebo-controlled trial aims to evaluate the safety and effectiveness of this combination therapy in adults undergoing the removal of impacted third molars. participants, aged 18-85, were divided into groups receiving different doses of ibuprofen and curcumin with liquorice root, compared to a control group receiving ibuprofen and placebo. the primary outcome is the sum of pain intensity differences over 8 hours, with secondary outcomes including total pain relief and the occurrence of any adverse events. the anticipated sample size, considering a 20% dropout rate, is 264 participants, ensuring the study is powered to detect significant differences in pain management efficacy.


Eligibility criteria:
inclusion criteria: * removal of 2 to 4 impacted third molars exclusion criteria: * pregnancy or breastfeeding * ibuprofen contraindications. * allergy to any of the intervention components.

Keywords: postoperative dental pain curcumin and licorice root ibuprofen anti-inflammatory properties molars
a new shoulder proprioceptive rehabilitative tool (srpt) for the evaluation of the role of the shoulder during reaching

Conditions: Shoulder Impingement Syndrome

Summary: the aim of the study focused on the creation of a rehabilitative measuring device (srpt-shoulder proprioceptive rehabilitation tool) and the development of the examination methodology for assessing the proprioception of the glenohumeral joint respect to scapula abduction, within the movement of antepulsion on the sagittal plane both in healthy subjects and in patients with shoulder impingement syndrome.


Eligibility criteria:
inclusion criteria: * right-handed * diagnosis of subacromial right impingement syndrome performed by the orthopedic specialist (nuclear magnetic resonance and/or ultrasound examination) * neer stages 1, 2 and 3 * presence of pain 3 \<vas\<8 at baseline * age between 55 and 65 years. exclusion criteria: * diabetes mellitus * inflammatory systemic diseases * cns and/or pns diseases * systemic infectious diseases * neoplastic diseases * assumption of antidepressants and/or anxiolytics and/or other medications that can affect attention and sensory * visual problems not properly compensated * previous surgery to the shoulder

Keywords: shoulder proprioception movement reaching
randomized trial of cryotherapy duration prior to high dose melphalan in myeloma patients

Conditions: Refractory Multiple Myeloma; Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma

Summary: the purpose of this study is to compare the effect of short-term (2 hours/120 minutes) and long-term (6 hours/360 minutes) schedules of crushed ice therapy (cryotherapy). patients that receive high dose melphalan for bone marrow transplantation commonly develop significant mouth pain and sores (oral mucositis) unless cryotherapy is utilized. the goal of this study is to scientifically determine (using randomization and a larger sample size) if a short-term schedule is as effective as the standard long-term schedule in preventing, or minimizing the symptoms involved with oral mucositis. the study is also trying to determine the best dose of melphalan and how patient's body breaks down melphalan and will obtain blood through central venous catheter to measure the amount of melphalan in patient's blood at specific times after the melphalan is infused

primary objectives: i. to measure the maximum inpatient mucositis grade after 120- vs. 360-minutes standardized cryotherapy regimens in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplantation at ohio state medical center. secondary objectives: i. to develop a pharmacokinetic model predicting variability in unbound serum melphalan area under the concentration-time curve (auc). ii. to compare the neutropenic fever and bacteremia incidence after 120- vs. 360-minute cryotherapy regimens. iii. to compare patient-reported mucositis-related symptoms up until discharge utilizing the patient-reported oral mucositis symptoms scale (proms) after 120- vs 360-minute cryotherapy regimens. outline: patients are randomized to 1 of 2 treatment arms. arm i: beginning fifteen minutes before melphalan treatment, patients receive 1 ounce of shaved ice in their mouth, allow it to melt and then replenish it immediately for 120 minutes. arm ii: beginning fifteen minutes before melphalan treatment, patients receive 1 ounce of shaved ice in their mouth, allow it to melt and then replenish it immediately for 360 minutes.

Eligibility criteria:
inclusion criteria: * patients must be diagnosed with multiple myeloma be admitted for autologous stem cell transplantation * age \> 18 years * patients or their legal representatives must be able to read, understand and provide informed consent to participate in the trial exclusion criteria: * any other medical condition, including mental illness or substance abuse, deemed by the principal investigator to likely interfere with a patient's ability to sign informed consent, cooperate and participate in the study, or interfere with the interpretation of the results

Keywords: cryotherapy melphalan mucositis
allogeneic bone marrow mesenchymal stem cells transplantation in patients with liver failure caused by hepatitis b virus (hbv)

Conditions: Liver Failure

Summary: allogeneic bone marrow mesenchymal stem cells transplantation in patients with liver failure caused by hepatitis b virus (hbv)


Eligibility criteria:
inclusion criteria: * liver failure caused by hbv * model for end-stage liver disease (meld) \< 30 exclusion criteria: * liver failure caused by other reasons, such as autoimmune diseases, alcohol, drug and so on. * history of moderate to severe hepatic encephalopathy or variceal bleeding during the last two months before enrollment. * severe problems in other vital organs (e.g.the heart,renal or lungs). * tumor on ultrasonography, ct or mri examination. * pregnant or lactating women. * hiv infection.

Keywords: abmlf allogenic bone marrow mesenchymal stem cells liver failure transplantation